~~<i id='286CCD3A6C'><strike id='286CCD3A6C'><tt id='286CCD3A6C'><pre id='286CCD3A6C'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

explore

entertainment

author：fashion 2025-09-30 12:11:01 - browse：9642

The Roche booth at ESMO in Madrid. — Roche's booth at the 2023 ESMO conference. Andrew Joseph/STAT

MADRID — A Roche drug lowered the risk of recurrence or death by 76% versus chemotherapy for patients with a type of early non-small cell lung cancer, according to data from a Phase 3 trial presented Saturday.

The findings, which Roche is planning to submit to regulators, could give patients with early-stage ALK-positive cancers another option. The standard treatment after surgery for these patients is chemotherapy.

The results from the Alina trial were presented here at the annual meeting of the European Society for Medical Oncology.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Malaria cases in Florida and Texas: Here’s what you need to know
Next article： What we know about the American soldier detained in North Korea

explore

leisure time

hotspot

focus

ElaineChenofSTAT,upperleft,talkedaboutobesitydrugswith,clockwise,RaymondStevenofStructureTherapeutic

WSS

Britain’s MI6 chief says his spies are using AI to disrupt flow of weapons to Russia

Asa Hutchinson previews new plan to reform federal law enforcement if elected in 2024

Ford plant in Missouri shuts down over 'possible threat,' sheriff's office says

UK homeowners get some respite as inflation falls by more than anticipated to a 15

More hospitals are billing patients as online messages surge

Snackable artificial intelligence, expert AI, and the pharma industry

explore

entertainment

explore

In Memoriam: Notable people who died in 2023

A rare thyroid diagnosis led to unexpected, all

Trump demands the U.S. pay no more for drugs than other countries … again

Humana sues Biden admin over Medicare Advantage audit rule

Drug repurposing or repositioning? The language matters

Flagship, Pfizer team up in deal worth up to $7 billion

Moonlake's readout produced a cash windfall. Risks remain

What we know about the American soldier detained in North Korea

After affirmative action ruling, medical educators look to 'holistic review'

'Make People Better': The CRISPR babies story you probably don't know

explore

ER docs worry over extreme heat as a 'mass casualty event'

Covid hospitalizations on the rise, Humana says

Amazon on where the company's health care bets are headed next

ER docs worry over extreme heat as a 'mass casualty event'

A new House health package & hospitals’ new site

What drug price negotiations mean for Medicare Part D

leisure time

hotspot

focus

focus